ACM
SNDX icon

Aster Capital Management’s Syndax Pharmaceuticals SNDX Stock Holding History

Aster Capital Management’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-167
Closed -$2.61K – 1529
2025
Q1 		$2.61K Buy
+167
New +$2.35K ﹤0.01% 1164
2024
Q4 		– Sell
-248
Closed -$4.77K – 1491
2024
Q3 		$4.77K Buy
+248
New +$5.12K ﹤0.01% 901

Other funds holding SNDX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SC
Stempoint Capital New York $522M AUM 281.95% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Aster Capital Management's SNDX Position: Q2 2025 in Review

Aster Capital Management sold out of Syndax Pharmaceuticals (SNDX) in Q2 2025, closing a stake of 167 shares — an estimated $2.61K sold.

Aster Capital Management first reported a position in SNDX in Q3 2024 and held it in 2 quarters. The position peaked at $4.77K in Q3 2024. 216 funds tracked by Wall St. Rank hold SNDX as of Q2 2025.

  • Aster Capital Management reported no remaining Syndax Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Aster Capital Management sold 167 Syndax Pharmaceuticals shares in Q2 2025, an estimated $2.61K.
  • Aster Capital Management first reported a position in Syndax Pharmaceuticals in Q3 2024 and held it in 2 quarters.
  • Aster Capital Management's Syndax Pharmaceuticals position peaked at $4.77K in Q3 2024.
  • 216 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q2 2025.

Based on Aster Capital Management's 13F filing for Q2 2025, filed 14 Aug 2025.